Engineering Soluble Recombinant BCMA for Ide‐Cel Labeling
European Journal of Immunology · 2026-07 · 56 (7)
DOI: 10.1002/eji.70251 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, online erschienen am 29.07.2026. Verfasst von Ly Phuong Vy Nguyen und 13 weiteren Autor:innen. Beteiligte Einrichtung: INSERM U1262, UMR CNRS 7276, Université de Limoges, Limoges, France. Hauptthemen laut MEDLINE: B-Cell Maturation Antigen, Receptors, Chimeric Antigen, Multiple Myeloma, Immunotherapy, Adoptive. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intergroupe Francophone du Myélome, Ligue Contre Le Cancer, French National Agency.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)‐T‐based strategies target the B‐cell maturation antigen (BCMA) expressed on the surface of malignant plasma cells in patients with multiple myeloma (MM). Idecabtagene vicleucel (ide‐cel), an anti‐BCMA CAR‐T therapy, has shown promising results in the treatment of relapsed or refractory multiple myeloma (R/RMM). Notably, the extent of CAR‐T cell expansion correlates with objective response rates and complete responses, indicating that monitoring CAR‐T cells is critical for predicting clinical outcomes in these patients. Although several tools are available to monitor CAR‐T cells in patient blood samples, they remain costly, prompting us to develop novel fluorescent and soluble BCMA reagents for CAR‐T cell labeling. BCMA is a type III transmembrane protein, and we found that a recombinant construct consisting of the BCMA extracellular domain fused to green fluorescent protein (GFP) failed to traffic through the Golgi apparatus and was not secreted. Incorporation of the interferon‐α2 signal peptide restored intracellular trafficking and enabled efficient secretion of soluble BCMA‐GFP and BCMA‐mCherry fusion proteins. These reagents specifically labeled anti‐BCMA CAR‐T cells. Overall, our results establish a cost‐effective method to generate soluble BCMA probes and provide accessible tools for monitoring CAR‐T cells in translational settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INSERM U1262, UMR CNRS 7276, Université de Limoges, Limoges, France.
- IRMETIST, INSERM U1313, Université de Poitiers, Poitiers, France.
- Inserm U1111, CNRS UMR 5308, CIRI, Faculté de Médecine Jacques Lisfranc, Saint-Priest-en-Jarez, France.
- Immunology Laboratory, CHU Saint-Etienne, Saint-Etienne, France.
- Service D'immunologie et Inflammation, CHU de Poitiers, Poitiers, France.
- Service D'oncologie Hématologique et de Thérapie Cellulaire CHU de Poitiers, Poitiers, France.
Förderung
- Intergroupe Francophone du Myélome
- Ligue Contre Le Cancer
- French National Agency
- Conseil Régional Nouvelle Aquitaine
Zitieren
APA
Nguyen, L. P. V., Oblet, C., Barbarin, A., Waeckel, L., Kotaich, F., Petit, C., Mabily, M., Carrion, C., Herbelin, A., Gombert, J. M., Leleu, X., Chalayer, E., Roussel, M., & Legembre, P. (2026). Engineering Soluble Recombinant BCMA for Ide‐Cel Labeling. European Journal of Immunology, 56(7). https://doi.org/10.1002/eji.70251
Vancouver
Nguyen LPV, Oblet C, Barbarin A, Waeckel L, Kotaich F, Petit C, et al. Engineering Soluble Recombinant BCMA for Ide‐Cel Labeling. European Journal of Immunology. 2026;56(7). doi:10.1002/eji.70251
BibTeX
@article{Nguyen2026,
author = {Nguyen, Ly Phuong Vy and Oblet, Christelle and Barbarin, Alice and Waeckel, Louis and Kotaich, Farah and Petit, Clara and Mabily, Marine and Carrion, Claire and Herbelin, André and Gombert, Jean Marc and Leleu, Xavier and Chalayer, Emilie and Roussel, Murielle and Legembre, Patrick},
title = {Engineering Soluble Recombinant BCMA for Ide‐Cel Labeling},
journal = {European Journal of Immunology},
year = {2026},
volume = {56},
number = {7},
doi = {10.1002/eji.70251}
}
EUVIMED